Literature DB >> 12393482

Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion.

Austen Worth1, Kanchana Rao, David Webb, Judith Chessells, Jane Passmore, Paul Veys.   

Abstract

Juvenile myelomonocytic leukemia (JMML) is a rare pediatric malignancy. Hematopoietic stem cell transplantation (SCT) is the only curative approach. However, relapse after SCT remains the major cause of treatment failure. Unlike most other pediatric malignancies, JMML may be susceptible to a graft-versus-leukemia (GVL) effect, although, unlike chronic myeloid leukemia, reports of response to donor lymphocyte infusions (DLIs) remain scanty. This is the first report that describes the successful treatment of relapsed JMML with DLI in the absence of further chemotherapy and provides definite proof of a GVL effect in JMML.

Entities:  

Mesh:

Year:  2002        PMID: 12393482     DOI: 10.1182/blood-2002-07-2011

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Alla Berezovskaya; Andrew P Murray; Sascha Ansén; Seiji Kojima; Lee M Nadler
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

2.  Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Authors:  Hemalatha G Rangarajan; Marcelo S F Pereira; Ruta Brazauskas; Andrew St Martin; Ashleigh Kussman; Ezgi Elmas; Michael R Verneris; Shahinaz M Gadalla; Steven G E Marsh; Sophie Paczesny; Stephen R Spellman; Stephanie J Lee; Dean A Lee
Journal:  Transplant Cell Ther       Date:  2021-08-15

Review 3.  Juvenile myelomonocytic leukemia.

Authors:  Charlotte Marie Niemeyer; Christian Kratz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 4.  Juvenile myelomonocytic leukemia.

Authors:  Charlotte Marie Niemeyer; Christian Kratz
Journal:  Curr Treat Options Oncol       Date:  2003-06

5.  Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.

Authors:  Yozo Nakazawa; Kazuyuki Matsuda; Takashi Kurata; Akane Sueki; Miyuki Tanaka; Kazuo Sakashita; Chihaya Imai; Matthew H Wilson; Kenichi Koike
Journal:  J Hematol Oncol       Date:  2016-03-16       Impact factor: 17.388

6.  Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.

Authors:  Shivani Y Upadhyay; Satiro N De Oliveira; Theodore B Moore
Journal:  J Investig Med High Impact Case Rep       Date:  2017-09-08

Review 7.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.